Search Result

Results for "

KCNQ2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (2) Histamine Receptor (1) mAChR (2) MARCKS (2) Potassium Channel (23) Reference Standards (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cardiovascular Disease (2) Inflammation/Immunology (1) Neurological Disease (23)
Click Chemistry:	Alkynes (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122114

ICA-27243 1 Publications Verification	Potassium Channel	Neurological Disease
ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC₅₀ of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects ^[2].

HY-108577

XE991 dihydrochloride 3 Publications Verification	Potassium Channel	Neurological Disease
XE991 dihydrochloride, a *Kv7 (KCNQ) channels* blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC₅₀s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-108577A

XE991 3 Publications Verification	Potassium Channel	Neurological Disease
XE 991 dihydrochloride, a *Kv7 (KCNQ) channels* blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC₅₀s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-18063

ML252	Potassium Channel Cytochrome P450	Neurological Disease
ML252 is a selective inhibitor of **KCNQ2 (Kv7.2) channel with an IC₅₀*s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3* and KCNQ4, respectively. ML252 also inhibits Cytochrome P450 with IC₅₀s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant ^[2].

HY-101396

ICA-069673 3 Publications Verification	Potassium Channel	Neurological Disease
ICA-069673 is a *KCNQ2/Q3* potassium channel activator. ICA-069673 demonstrates greater selectivity for *KV7.2/7.3* over KV7.3/KV7.5, with EC₅₀s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells ^[2].

HY-108587

ICA 110381	Potassium Channel	Neurological Disease
ICA 110381 is an orally active *Kv7.2/Kv7.3* (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a *KCNQ2*/Q3 activator (EC₅₀=0.38 μM) as well as *KCNQ1* antagonist (IC₅₀=15 μM) .

HY-157485

Ebio1	Potassium Channel	Others
Ebio1 is a selective voltage-gated potassium channel *KCNQ2* activator. Ebio1 activates *KCNQ2* by generating an extended channel gate with greater conductance at a saturation voltage (+50 mV) .

HY-145016

HN37	Potassium Channel	Neurological Disease
HN37 as a potent and chemically stable antiepileptic agent candidate, with an EC₅₀ of 37 nM for *KCNQ2* . HN37 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-123264

RL648_81	Potassium Channel	Neurological Disease
RL648_81 is a specific KQT-like subfamily 2/3 (KCNQ2/3) activator with an EC₅₀ of 190 nM. RL648_81 robustly shifts the V1/2 of KCNQ2/3 channels towards hyperpolarized potentials.RL648_81 does not shift the V1/2 of either KCNQ4 or KCNQ5.RL648_81 has?the?potential?for?neurologic disorders associated with neuronal hyperexcitability research .

HY-108592

UCL 2077	Potassium Channel	Cardiovascular Disease Neurological Disease
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca ²⁺ currents. UCL 2077 blocks *KCNQ1- and KCNQ2*-containing K ⁺ channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias ^[2] .

HY-113616A

VU0364572 TFA	MARCKS mAChR	Neurological Disease
VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC₅₀ of 0.11 μM. VU0364572 TFA has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 TFA is CNS penetrant .

HY-RS07174

KCNQ2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KCNQ2 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNQ2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KCNQ2 Human Pre-designed siRNA Set A KCNQ2 Human Pre-designed siRNA Set A

HY-180873

KCNQ2 modulator-1	Potassium Channel	Neurological Disease
KCNQ2 modulator-1 is a *KCNQ2* modulator.

HY-RS17110

Kcnq2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kcnq2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kcnq2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kcnq2 Mouse Pre-designed siRNA Set A Kcnq2 Mouse Pre-designed siRNA Set A

HY-RS23555

Kcnq2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kcnq2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kcnq2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kcnq2 Rat Pre-designed siRNA Set A Kcnq2 Rat Pre-designed siRNA Set A

HY-172140

Ebio3	Potassium Channel	Neurological Disease
Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC₅₀ of 1.2 nM. Ebio3 binds to the *KCNQ2* channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .

HY-115823

ztz240	Potassium Channel	Neurological Disease
ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC₅₀=6.1 μM; *KCNQ4: EC₅₀*=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .

HY-18063A

ML252 hydrochloride	Potassium Channel Cytochrome P450	Neurological Disease
ML252 hydrochloride is a selective inhibitor of **KCNQ2 (Kv7.2) channel with IC₅₀*s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3* and KCNQ4, respectively. ML252 hydrochloride also inhibits Cytochrome P450 with IC₅₀s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 hydrochloride shows highly brain penetrant ^[2].

HY-172141

Ebio2	Potassium Channel	Cardiovascular Disease
Ebio2 is a potent *KCNQ2* activator .

HY-181128

QO-83	Potassium Channel	Neurological Disease
QO-83, Retigabine analogue, is a voltage-gated potassium channel KCNQ2 (Kv7.2) activator with an EC₅₀ of 0.56 μM. QO-83 binds to a single hydrophobic pocket of KCNQ2-CaM complex in closed conformation. QO-83 induces a negative shift in the voltage-dependent activation curve of KCNQ2 channels, increasing the channel's voltage sensitivity. QO-83 can be used for the research of epilepsies .

HY-130070

QO-40	Potassium Channel	Neurological Disease
QO-40, a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative, is a *KCNQ2/KCNQ3* K ⁺ channels activator with an EC₅₀ of 6.94 μM. QO-40 stimulated Ca ²⁺-activated K ⁺ current (I_K(Ca)) with an EC₅₀ value of 2.3 μM in pituitary GH3 lactotrophs ^[2].

HY-113616

VU0364572	mAChR MARCKS	Neurological Disease
VU0364572 is a selective allosteric agonist of the M1 muscarinic receptor with an EC₅₀ of 0.11 μM. VU0364572 has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 is orally active and is CNS penetrant .

HY-108577R

XE991 dihydrochloride (Standard)	Potassium Channel	Neurological Disease
XE991 dihydrochloride (Standard) is the analytical standard of XE991 dihydrochloride. This product is intended for research and analytical applications. XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-168214

Kv7.2/Kv7.3 agonist 1	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC₅₀ of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED₅₀ of 12.02 and 9.63 mg/kg .

HY-182435

CLE-030	Potassium Channel	Neurological Disease
CLE-030 is a *KCNQ2* agonist with non-gating-dependent current-modulating activity . CLE-030 modulates neuronal network activity. CLE-030 can be used in studies related to pain, epilepsy and benign familial neonatal convulsions ^[2].

HY-118807A

Mepyramine hydrochloride Pyrilamine hydrochloride	Histamine Receptor Potassium Channel	Neurological Disease Inflammation/Immunology
Mepyramine hydrochloride (Pyrilamine hydrochloride) is a selective histamine H1 receptor antagonist and *KCNQ* channel inhibitor, with an IC₅₀ of 12.5 μM against *KCNQ2/Q3*. Mepyramine hydrochloride shows no activity against allergic asthma in mice when used alone, but modulates the effect of JNJ 7777120 (HY-13508) on allergic asthma in mice; it inhibits the development of morphine physical dependence and increases histamine levels in mouse brains. Mepyramine hydrochloride can be used in studies related to seizures, convulsions, allergic asthma and morphine physical dependence ^[2] .

HY-108577AR

XE991 (Standard)	Potassium Channel Reference Standards	Neurological Disease
XE991 (Standard) is the analytical standard of XE991 (HY-108577A). This product is intended for research and analytical applications. XE 991, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC₅₀s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-101396R

ICA-069673 (Standard)	Potassium Channel Reference Standards	Neurological Disease
ICA-069673 (Standard) is the analytical standard of ICA-069673 (HY-101396). This product is intended for research and analytical applications. ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells ^[2].

Cat. No.	Product Name		Classification

HY-145016

HN37		Alkynes
HN37 as a potent and chemically stable antiepileptic agent candidate, with an EC₅₀ of 37 nM for *KCNQ2* . HN37 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-172140

Ebio3		Alkynes
Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC₅₀ of 1.2 nM. Ebio3 binds to the *KCNQ2* channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .

HY-172141

Ebio2		Alkynes
Ebio2 is a potent *KCNQ2* activator .

KCNQ2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
KCNQ2 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNQ2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kcnq2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Kcnq2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kcnq2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kcnq2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Kcnq2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kcnq2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: